While a majority of adults recognize leukemia as a blood cancer, a new survey by The Leukemia & Lymphoma Society (LLS) found that a low percentage of respondents associate the following diseases with a blood cancer: lymphoma (including Hodgkin’s lymphoma), myeloma, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs).

Already approved in later stage and high-risk cHL, the goal of ongoing Adcetris studies is to “develop curative treatments that improve survival while also reducing toxicity,” Jeremy Abramson, director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital and principal investigator for the Phase II trial, said in a statement.  

California-based Gossamer Bio announced Monday that it is discontinuing the development of its lymphoma candidate GB5121 following two patient deaths in the Phase Ib/II STAR-CNS study.

An independent panel of advisers voted to approve Genentech’s Polivy after internal FDA staff raised concerns regarding the efficacy and risk-benefit profile as a first-line treatment for large B-cell lymphoma.

FDA advisers raised concerns regarding the efficacy and risk-benefit profile of Genentech’s Polivy as a first-line treatment for large B-cell lymphoma ahead of a March 9 advisory committee meeting.

It might seem like luck for a company to trip over a multi-billion dollar COVID treatment already lurking in its pipeline – but perhaps not so much when that company, Gilead, has been at the leading edge of antiviral R&D for decades.

On Tuesday, Curis, Inc. announced that the FDA has allowed patient enrollment to resume in the monotherapy phase of its TakeAim Leukemia Phase I/II trial studying emavusertib.

Johnson & Johnson and AbbVie’s big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check for more than two years longer than the standard regimen alone in older patients, according to data presented on Friday.

The U.S. Food and Drug Administration said on Wednesday it has withdrawn the health regulator’s approval for TG Therapeutics Inc.’s lymphatic cancer treatment Ukoniq over concerns of higher risk of death in patients receiving the drug.

The long weekend saw three established drugs developed by Bristol Myers Squibb, Novartis, and Roche score new approvals from the U.S. Food and Drug Administration.